[Survival of patients with malignant astrocytomas according to the expression of Ki67 antigen in a pediatric hospital].
BACKGROUND
Pediatric patients with malignant gliomas and same histological diagnosis respond distinctly to treatment. It is thus necessary to determine other factors that may influence the response to treatment and survival. Over expression of the Ki67 protein has been associated with poor treatment response. The aim of this study was to determine if the expression of this antigen influences survival of patients treated for malignant gliomas in the CMN SXXI Pediatrics Hospital.


METHODS
We included patients with anaplasic astrocitoma or glioblastoma multiforme seen at our hospital between 1995 and 2005. We determined the expression of Ki67 by immunohistochemistry and correlated the findings with tumor histology and patient survival.


RESULTS
Of the 21 patients studied, 12 overexpressed antigen Ki67. There was no significant association between over expression of Ki67 and survival, although we observed a clinical association. Over expression of Ki67 correlated with more aggressive histology. Being under the age of 11 was a poor prognostic factor. Overall survival was 49% at 120 months.


CONCLUSIONS
Being young (under 11 years) is a marker of poor prognosis among pediatric patients with anaplasic astrocytoma or glioblastoma multiforme. Overexpression expression of antigen Ki67 is associated with histology and may be associated with poor survival among patients treated in our hospital.
López-Aguilar
Enrique
E
Departamento de Oncología Pediátrica, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., México. elopezaguilar@hotmail.com
Sepúlveda Vildósola
Ana Carolina
AC
Rioscovián-Soto
Ana Paulina
AP
Gascón-Lastiri
Graciela
G
Rojas-Puentes
Federico
F
Siordia-Reyes
Georgina
G
Diegopérez-Ramírez
Jaime
J
De la Cruz-Yáñez
Hermilo
H
Barrientos-Salcedo
Carolina
C
D000293:Adolescent; D001254:Astrocytoma / Q000378:metabolism* / Q000401:mortality*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006776:Hospitals, Pediatric; D006801:Humans; D019394:Ki-67 Antigen / Q000096:biosynthesis*; D008297:Male; D011379:Prognosis; D015996:Survival Rate
D019394:Ki-67 Antigen